KR20230154900A - 갈락토스-결핍 면역글로불린의 이중기능성 분해제 - Google Patents
갈락토스-결핍 면역글로불린의 이중기능성 분해제 Download PDFInfo
- Publication number
- KR20230154900A KR20230154900A KR1020237033102A KR20237033102A KR20230154900A KR 20230154900 A KR20230154900 A KR 20230154900A KR 1020237033102 A KR1020237033102 A KR 1020237033102A KR 20237033102 A KR20237033102 A KR 20237033102A KR 20230154900 A KR20230154900 A KR 20230154900A
- Authority
- KR
- South Korea
- Prior art keywords
- optionally substituted
- moiety
- group
- groups
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163159383P | 2021-03-10 | 2021-03-10 | |
| US63/159,383 | 2021-03-10 | ||
| PCT/US2022/019658 WO2022192478A1 (en) | 2021-03-10 | 2022-03-10 | Bifunctional degraders of galactose-deficient immunoglobulins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230154900A true KR20230154900A (ko) | 2023-11-09 |
Family
ID=83227063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237033102A Pending KR20230154900A (ko) | 2021-03-10 | 2022-03-10 | 갈락토스-결핍 면역글로불린의 이중기능성 분해제 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240309114A1 (https=) |
| EP (1) | EP4304579A1 (https=) |
| JP (1) | JP2024509282A (https=) |
| KR (1) | KR20230154900A (https=) |
| CN (1) | CN116997337A (https=) |
| AU (1) | AU2022232620A1 (https=) |
| BR (1) | BR112023017702A2 (https=) |
| CA (1) | CA3211335A1 (https=) |
| IL (1) | IL305665A (https=) |
| MX (1) | MX2023010424A (https=) |
| WO (1) | WO2022192478A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023013274A (es) * | 2021-05-17 | 2023-11-30 | Biohaven Therapeutics Ltd | Composiciones que incluyen potenciadores de tratamientos conjugados. |
| EP4370157A1 (en) | 2021-07-14 | 2024-05-22 | Lycia Therapeutics, Inc. | Asgpr cell surface receptor binding compounds and conjugates |
| WO2024228935A1 (en) * | 2023-04-29 | 2024-11-07 | Biohaven Therapeutics Ltd. | Bifunctional degraders of galactose-deficient immunoglobulins |
| WO2026083257A1 (en) | 2024-10-14 | 2026-04-23 | Biohaven Therapeutics Ltd. | Antigen-specific degraders of immunoglobulin a and their uses |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8440191B2 (en) * | 2005-11-18 | 2013-05-14 | Tufts Medical Center | Clearance of abnormal IGA1 in IGA1 deposition diseases |
| PL2991683T3 (pl) * | 2013-05-02 | 2020-03-31 | Glykos Finland Oy | Koniugaty glikoproteiny lub glikanu z toksycznym ładunkiem |
| SG11201606761RA (en) * | 2014-02-21 | 2016-09-29 | Ecole Polytecnique Federale De Lausanne Epfl Epfl Tto | Glycotargeting therapeutics |
| PL3145934T3 (pl) * | 2014-05-19 | 2021-08-16 | Pfizer Inc. | Podstawione związki 6,8-dioksabicyklo[3.2.1]oktano-2,3-diolu jako środki kierujące do ASGPR |
| EP3773727A4 (en) * | 2018-04-09 | 2022-05-04 | Yale University | BIFUNCTIONAL SMALL MOLECULES TO TARGETING THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS |
-
2022
- 2022-03-10 WO PCT/US2022/019658 patent/WO2022192478A1/en not_active Ceased
- 2022-03-10 BR BR112023017702A patent/BR112023017702A2/pt unknown
- 2022-03-10 EP EP22767951.1A patent/EP4304579A1/en active Pending
- 2022-03-10 CA CA3211335A patent/CA3211335A1/en active Pending
- 2022-03-10 JP JP2023555333A patent/JP2024509282A/ja active Pending
- 2022-03-10 MX MX2023010424A patent/MX2023010424A/es unknown
- 2022-03-10 KR KR1020237033102A patent/KR20230154900A/ko active Pending
- 2022-03-10 AU AU2022232620A patent/AU2022232620A1/en active Pending
- 2022-03-10 CN CN202280020292.8A patent/CN116997337A/zh active Pending
- 2022-03-10 US US18/548,113 patent/US20240309114A1/en active Pending
- 2022-03-10 IL IL305665A patent/IL305665A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240309114A1 (en) | 2024-09-19 |
| MX2023010424A (es) | 2023-09-18 |
| WO2022192478A1 (en) | 2022-09-15 |
| EP4304579A1 (en) | 2024-01-17 |
| CA3211335A1 (en) | 2022-09-15 |
| IL305665A (en) | 2023-11-01 |
| JP2024509282A (ja) | 2024-02-29 |
| BR112023017702A2 (pt) | 2023-12-12 |
| AU2022232620A1 (en) | 2023-09-21 |
| CN116997337A (zh) | 2023-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20230154900A (ko) | 갈락토스-결핍 면역글로불린의 이중기능성 분해제 | |
| JP7241811B2 (ja) | 四級化チューブリシン化合物の複合体 | |
| JP7430643B2 (ja) | カンプトテシンペプチドコンジュゲート | |
| KR102235870B1 (ko) | 접합체 화합물 | |
| JP7527978B2 (ja) | カンプトテシンコンジュゲート | |
| KR102938500B1 (ko) | 항체 약물 접합제용 친수성 링커 | |
| KR20230004453A (ko) | 캄프토테신 유도체 및 이의 접합체 | |
| US20220241423A1 (en) | Camptothecine antibody-drug conjugates and methods of use thereof | |
| JP7846624B2 (ja) | ペプチド含有リンカーとの部位特異的抗体－薬物コンジュゲート | |
| JP2024506300A (ja) | 免疫刺激化合物及びコンジュゲート体 | |
| CN114728073A (zh) | 药物从生物活性化合物的内化缀合物的选择性释放 | |
| CN112955434B (zh) | 包含喹啉衍生物的药物偶联物 | |
| JP2021513990A (ja) | 疎水性アウリスタチンｆ化合物およびそのコンジュゲート | |
| US10081668B2 (en) | Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection | |
| US20240197907A1 (en) | Dual-Cleavage Ester Linkers for Antibody-Drug Conjugates | |
| JP2004510709A (ja) | ペプチドと親油性ベクターとを溶液中で結合するための方法およびその使用 | |
| EP4402178A2 (en) | Conjugated antibodies for treating diseases | |
| RU2859790C2 (ru) | Сложноэфирные линкеры с двойным расщеплением для конъюгатов антитело-лекарственное средство | |
| CN116847844A (zh) | 喜树碱抗体-药物缀合物及其使用方法 | |
| WO2024098023A2 (en) | Interferon alpha polypeptides and conjugates | |
| HK40076663A (en) | Selective drug release from internalized conjugates of biologically active compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |